| 2025-07-08 | -36.6% | earnings | Seeking Alpha | RxSight stock slides on lower Q2 revenue guidance |
| 2025-07-08 | -36.6% | legal | SEC EDGAR | RXST 8-K: 2.02 and (SEC Filing) |
| 2025-07-08 | -36.6% | legal | Stock Titan | RXST SEC Filings - Rxsight, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan |
| 2025-07-09 | -34.7% | earnings | Seeking Alpha | RxSight's Revised Guidance Reflects Deeper Market Shifts (Rating Downgrade) |
| 2025-07-09 | -34.7% | analyst | Seeking Alpha | RxSight stock falls after Wells, BTIG downgrade on poor results |
| 2025-07-09 | -34.7% | news | Seeking Alpha | Biggest stock movers Wednesday: VRNA, WPP, AEHR, EVTL, RXST, BTCS and more |
| 2025-07-09 | -34.7% | earnings | Investopedia | RxSight Stock Sinks 50% as Medical Device Maker Slashes Revenue Outlook - Investopedia |
| 2025-04-02 | -31.4% | earnings | GlobeNewswire | RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance - GlobeNewswire |
| 2022-01-10 | +28.8% | legal | SEC EDGAR | RXST 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-04-03 | -27.3% | analyst | Seeking Alpha | RxSight: Navigating Market Headwinds Amid Intensifying Competition (Downgrade) |
| 2025-04-03 | -27.3% | earnings | Seeking Alpha | Rxsight adjusts 2025 revenue guidance to $160M-$175M amid premium IOL market challenges |
| 2025-04-03 | -27.3% | earnings | Seeking Alpha | RxSight, Inc. (RXST) Q1 2025 Preliminary Results Conference Call (Transcript) |
| 2025-04-03 | -27.3% | earnings | Seeking Alpha | RxSight plunges after guidance cut; BofA downgrades |
| 2025-04-03 | -27.3% | legal | SEC EDGAR | RXST 8-K: 2.02 (SEC Filing) |
| 2025-04-03 | -27.3% | earnings | Yahoo Finance | RxSight Plunges 44% After Slashing 2025 Guidance; Bank of America Downgrades Stock - Yahoo Finance |
| 2024-01-08 | +23.6% | legal | SEC EDGAR | RXST 8-K: 2.02 (SEC Filing) |
| 2024-08-05 | +16.6% | legal | SEC EDGAR | RXST 8-K: 2.02 (SEC Filing) |
| 2025-08-08 | -15.2% | earnings | Seeking Alpha | RxSight outlines $120M–$130M 2025 revenue target while intensifying customer success strategy |
| 2025-08-08 | -15.2% | earnings | Seeking Alpha | RxSight, Inc. (RXST) Q2 2025 Earnings Call Transcript |
| 2021-09-09 | -14.9% | legal | SEC EDGAR | RXST 8-K: 2.02 and (SEC Filing) |
| 2026-01-12 | +14.4% | earnings | Seeking Alpha | RxSight guides FY revenue above previous estimates, names new CFO |
| 2026-01-12 | +14.4% | legal | SEC EDGAR | RXST 8-K: 2.02, 5.02, 7.01 (SEC Filing) |
| 2026-01-12 | +14.4% | analyst | Investing.com | Stifel reiterates Hold rating on RxSight stock amid competition concerns - Investing.com |
| 2026-01-12 | +14.4% | news | Benzinga | Planet Labs PBC, Day One Biopharmaceuticals, Rxsight, SunOpta And Other Big Stocks Moving Higher On Monday - Benzinga |
| 2026-02-26 | -14.1% | earnings | Moby | RxSight, Inc. Q4 2025 Earnings Call Summary |
| 2026-02-26 | -14.1% | earnings | MarketBeat | RxSight Q4 Earnings Call Highlights |
| 2026-02-26 | -14.1% | earnings | GuruFocus.com | RxSight Inc (RXST) Q4 2025 Earnings Call Highlights: Navigating Challenges with Strategic ... |
| 2026-02-26 | -14.1% | earnings | Seeking Alpha | RxSight outlines $120M–$135M 2026 revenue guidance while strengthening commercial initiatives |
| 2026-02-26 | -14.1% | earnings | Seeking Alpha | RxSight, Inc. (RXST) Q4 2025 Earnings Call Transcript |
| 2026-02-26 | -14.1% | earnings | Investing.com | Needham reiterates Buy on RxSight stock, keeps $13 target - Investing.com |
| 2026-01-11 | +14.0% | earnings | Quiver Quantitative | RxSight, Inc. Reports Preliminary Financial Results for Q4 and Full-Year 2025; Announces Appointment of New CFO - Quiver Quantitative |
| 2026-01-11 | +14.0% | executive | Stock Titan | Adjustable cataract lens maker adds more devices and a new finance chief - Stock Titan |
| 2026-01-10 | +14.0% | news | simplywall.st | We're Hopeful That RxSight (NASDAQ:RXST) Will Use Its Cash Wisely - simplywall.st |
| 2022-11-07 | +13.6% | legal | SEC EDGAR | RXST 8-K: 2.02 and (SEC Filing) |
| 2024-11-07 | -13.5% | legal | SEC EDGAR | RXST 8-K: 2.02 and (SEC Filing) |
| 2025-11-06 | +13.3% | earnings | Seeking Alpha | RxSight narrows 2025 revenue guidance to $125M–$130M while elevating gross margin outlook amid evolving commercial strategy |
| 2025-11-06 | +13.3% | earnings | Seeking Alpha | RxSight, Inc. (RXST) Q3 2025 Earnings Call Transcript |
| 2022-01-04 | -13.1% | legal | SEC EDGAR | RXST 8-K: 5.02 and (SEC Filing) |
| 2025-05-08 | -12.9% | earnings | Seeking Alpha | RxSight, Inc. (RXST) Q1 2025 Earnings Call Transcript |
| 2026-02-25 | -11.7% | earnings | Seeking Alpha | RxSight Non-GAAP EPS of -$0.03 beats by $0.17, revenue of $32.6M in-line |
| 2026-02-25 | -11.7% | legal | SEC EDGAR | RXST 8-K: 2.02 and (SEC Filing) |
| 2026-02-25 | -11.7% | earnings | Quiver Quantitative | RxSight (RXST) Releases Q4 2025 Earnings: Revenue Down but Beats Estimates; Loss Narrows, EPS Beats - Quiver Quantitative |
| 2026-02-25 | -11.7% | earnings | Yahoo Finance | RxSight, Inc. (RXST) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance |
| 2026-02-25 | -11.7% | earnings | bitget.com | RxSight, Inc. (RXST) Posts Fourth Quarter Loss, Surpasses Revenue Expectations - bitget.com |
| 2023-03-06 | +11.2% | legal | SEC EDGAR | RXST 8-K: 2.02 and (SEC Filing) |
| 2025-04-09 | -11.0% | earnings | Seeking Alpha | RxSight downgraded at UBS after Q1 miss and guidance cut |
| 2024-12-20 | -10.9% | news | Yahoo Finance | Do You Believe in the Long-Term Growth Potential of RxSight (RXST)? - Yahoo Finance |
| 2026-03-19 | -10.4% | legal | SEC EDGAR | RXST 8-K: 5.02 (SEC Filing) |
| 2026-03-19 | -10.4% | executive | Stock Titan | RxSight (NASDAQ: RXST) details CFO sign-on bonus and corrects option vesting - Stock Titan |
| 2025-01-13 | -10.3% | legal | SEC EDGAR | RXST 8-K: 2.02 (SEC Filing) |
| 2026-04-02 | +10.2% | news | GlobeNewswire | RxSight, Inc. to Participate in the 25th Annual Needham Virtual Healthcare Conference |
| 2026-04-02 | +10.2% | news | Stock Titan | RxSight management joins Needham virtual healthcare event Apr. 16 - Stock Titan |
| 2026-04-02 | +10.2% | legal | Stock Titan | RXST SEC Filings - Rxsight, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan |
| 2025-12-22 | -9.6% | legal | SEC EDGAR | RXST 8-K: 5.02, 7.01 (SEC Filing) |
| 2025-12-22 | -9.6% | executive | Quiver Quantitative | RxSight, Inc. Announces Transition of Chief Financial Officer Shelley Thunen - Quiver Quantitative |
| 2025-09-08 | +9.5% | news | Seeking Alpha | RxSight, Inc. (RXST) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript |
| 2023-05-09 | +8.9% | legal | SEC EDGAR | RXST 8-K: 2.02 and (SEC Filing) |
| 2025-04-04 | +8.5% | analyst | Seeking Alpha | SA Analyst Rating Changes: CHTR, RIVN, EE, WASH, DV, LZ, RXST |
| 2021-08-01 | +8.5% | news | Zacks Investment Research | Should I buy RxSight (RXST) - Zacks Investment Research |
| 2021-07-31 | +8.5% | news | TradingView | RXST Stock Price and Chart — NASDAQ:RXST - TradingView |
| 2021-07-31 | +8.5% | earnings | MarketBeat | RxSight (RXST) Stock Price, News & Analysis - MarketBeat |
| 2025-12-23 | -7.1% | executive | Seeking Alpha | RxSight down on CFO transition |
| 2025-12-23 | -7.1% | legal | SEC EDGAR | RXST 8-K: 5.02 and 7.01 (SEC Filing) |
| 2023-02-08 | -6.7% | legal | SEC EDGAR | RXST 8-K: 1.01, 8.01 (SEC Filing) |
| 2025-07-22 | +6.6% | news | GlobeNewswire | RXST LOSS ALERT: Lose Money on RxSight, Inc. (NASDAQ: - GlobeNewswire |
| 2022-07-11 | -6.6% | legal | SEC EDGAR | RXST 8-K: 8.01 and (SEC Filing) |
| 2025-05-07 | -6.3% | earnings | Seeking Alpha | RxSight Non-GAAP EPS of -$0.03 beats by $0.05, revenue of $37.9M in-line |
| 2025-05-07 | -6.3% | legal | SEC EDGAR | RXST 8-K: 2.02 (SEC Filing) |
| 2024-02-28 | -6.0% | legal | SEC EDGAR | RXST 8-K: 2.02 (SEC Filing) |
| 2024-02-28 | -6.0% | news | Stock Titan | RxSight, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results - Stock Titan |
| 2026-04-20 | -6.0% | executive | Stock Titan | RxSight (RXST) COO exercises stock options, now holding over 79,000 shares - Stock Titan |
| 2025-07-15 | -5.8% | analyst | Seeking Alpha | Steris, Solventum upgraded, RxSight downgraded in Morgan Stanley's MedTech review |
| 2025-11-26 | +5.8% | news | simplywall.st | RxSight, Inc. (NASDAQ:RXST) institutional owners may be pleased with recent gains after 77% loss over the past year - simplywall.st |
| 2025-08-07 | -5.5% | earnings | Seeking Alpha | RxSight GAAP EPS of -$0.29 misses by $0.05, revenue of $33.6M in-line |
| 2025-08-07 | -5.5% | legal | SEC EDGAR | RXST 8-K: 2.02 (SEC Filing) |
| 2026-04-05 | +5.3% | earnings | Simply Wall St. | How The Story Is Shifting For RxSight (RXST) On Guidance Leadership And Valuation |
| 2026-01-22 | -5.0% | news | PR Newswire | INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. - RXST - PR Newswire |
| 2021-11-10 | +4.5% | legal | SEC EDGAR | RXST 8-K: 2.02 and (SEC Filing) |
| 2026-03-27 | -4.1% | news | Stock Titan | Vanguard realignment: RXST filings show 0 shares; subsidiaries report separately (RXST) - Stock Titan |
| 2024-08-13 | -4.0% | news | Seeking Alpha | Investing In The Future Of Cataract Surgery: The RxSight Advantage (NASDAQ:RXST) - Seeking Alpha |
| 2025-11-05 | -3.6% | earnings | Seeking Alpha | RxSight Non-GAAP EPS of -$0.04 beats by $0.19, revenue of $30.3M beats by $4.67M |
| 2025-11-05 | -3.6% | legal | SEC EDGAR | RXST 8-K: 2.02 (SEC Filing) |
| 2025-11-05 | -3.6% | news | Yahoo Finance | RxSight, Inc. Reports Third Quarter 2025 Financial Results - Yahoo Finance |
| 2025-08-15 | +3.5% | legal | SEC EDGAR | RXST 8-K: 5.02 (SEC Filing) |
| 2026-01-13 | -3.5% | news | Yahoo Finance | RxSight (RXST) Soars 14.1%: Is Further Upside Left in the Stock? - Yahoo Finance |
| 2025-10-22 | -3.3% | news | Quiver Quantitative | RxSight, Inc. to Report Third Quarter 2025 Financial Results on November 5, 2025 | RXST Stock News - Quiver Quantitative |
| 2023-12-06 | +3.2% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2025-12-12 | -3.1% | earnings | simplywall.st | RxSight, Inc.'s (NASDAQ:RXST) 28% Price Boost Is Out Of Tune With Revenues - simplywall.st |
| 2026-04-08 | -3.0% | news | GlobeNewswire | RxSight Highlights 300,000 Light Adjustable Lens Implant Milestone and Strong Scientific Presence at ASCRS 2026 |
| 2026-04-08 | -3.0% | news | Stock Titan | RxSight's cataract lens adjusted after surgery reaches 300,000 uses - Stock Titan |
| 2026-01-14 | -2.9% | news | Seeking Alpha | RxSight, Inc. (RXST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript |
| 2026-01-14 | -2.9% | news | Seeking Alpha | RxSight, Inc. (RXST) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow |
| 2024-05-09 | -2.9% | legal | SEC EDGAR | RXST 8-K: 1.01, 8.01 (SEC Filing) |
| 2025-08-04 | -2.9% | legal | SEC EDGAR | RXST 8-K: 5.02 (SEC Filing) |
| 2023-01-09 | +2.9% | legal | SEC EDGAR | RXST 8-K: 2.02, 8.01 (SEC Filing) |
| 2022-09-01 | +2.7% | analyst | TradingView | RXST Forecast — Price Target — Prediction for 2027 - TradingView |
| 2026-02-18 | -2.7% | earnings | Finviz | Earnings Preview: RxSight, Inc. (RXST) Q4 Earnings Expected to Decline - Finviz |
| 2025-09-12 | -2.5% | news | simplywall.st | Hopeful Week For Insiders Who Bought US$1.11m Of RxSight Stock - simplywall.st |
| 2023-11-11 | +2.5% | news | Forbes | RxSight | RXST Stock Price, Company Overview & News - Forbes |
| 2026-03-07 | -2.4% | earnings | Simply Wall St. | How The RxSight (RXST) Investment Story Is Shifting With New Guidance And CFO Change |
| 2022-08-08 | -2.4% | legal | SEC EDGAR | RXST 8-K: 1.01 and (SEC Filing) |
| 2022-08-08 | -2.4% | legal | SEC EDGAR | RXST 8-K: 2.02 and (SEC Filing) |
| 2022-10-11 | +2.4% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for RxSight (RXST) - Zacks Investment Research |
| 2025-04-05 | +2.3% | news | Seeking Alpha | Top 10 Russell 2000 weekly gainers and losers as Wall Street crashes |
| 2026-04-11 | +2.2% | earnings | MarketBeat | RxSight, Inc. (NASDAQ:RXST) Given Consensus Recommendation of "Reduce" by Analysts - MarketBeat |
| 2026-04-19 | -2.0% | earnings | Simply Wall St. | How The RxSight (RXST) Story Is Shifting With New Guidance And Street Price Targets |
| 2026-04-18 | -2.0% | news | Cổng thông tin điện tử tỉnh Lào Cai | RxSight (RXST) Stock: Mid-Year Review (Extends Gains) 2026-04-18 - Volatility Analysis - Cổng thông tin điện tử tỉnh Lào Cai |
| 2024-11-29 | -2.0% | news | Seeking Alpha | RxSight's Momentum In The Large Cataract Surgery Market Merits A Close Eye (RXST) - Seeking Alpha |
| 2023-08-07 | -1.9% | legal | SEC EDGAR | RXST 8-K: 2.02 and (SEC Filing) |
| 2025-12-19 | -1.9% | legal | SEC EDGAR | RXST 8-K: 5.02 (SEC Filing) |
| 2026-03-21 | -1.8% | earnings | Simply Wall St. | How The RxSight (RXST) Investment Story Is Shifting With New Guidance And CFO Transition |
| 2026-03-21 | -1.8% | earnings | Yahoo Finance | How The RxSight (RXST) Investment Story Is Shifting With New Guidance And CFO Transition - Yahoo Finance |
| 2025-06-07 | +1.6% | news | Seeking Alpha | RxSight: Valuation Blowout Creates Opportunity |
| 2025-06-07 | +1.6% | news | Seeking Alpha | RxSight Stock: Valuation Blowout Creates Opportunity (NASDAQ:RXST) - Seeking Alpha |
| 2023-04-23 | -1.1% | news | CoinCodex | RxSight, Inc. (RXST) Stock Forecast & Price Prediction 2026–2030 - CoinCodex |
| 2023-11-09 | +1.0% | legal | SEC EDGAR | RXST 8-K: 2.02 and (SEC Filing) |
| 2026-04-22 | +0.9% | news | GlobeNewswire | RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6 |
| 2026-04-22 | +0.9% | news | Stock Titan | RxSight pins down May 6 for first-quarter results and investor call - Stock Titan |
| 2025-09-20 | +0.7% | news | GlobeNewswire | INVESTOR CLASS ACTION: RxSight, Inc. Investors are Reminded - GlobeNewswire |
| 2023-07-05 | +0.6% | legal | SEC EDGAR | RXST 8-K: 1.01, 1.02, 2.03, 3.03 (SEC Filing) |
| 2025-02-25 | -0.6% | legal | SEC EDGAR | RXST 8-K: 2.02 (SEC Filing) |
| 2025-09-22 | +0.6% | news | Seeking Alpha | The Bottom Fishing Club - RxSight: A Ski-Jump Reversal Pattern? |
| 2025-09-22 | +0.6% | news | Seeking Alpha | The Bottom Fishing Club - RxSight: A Ski-Jump Reversal Pattern? (NASDAQ:RXST) - Seeking Alpha |
| 2022-03-08 | -0.5% | legal | SEC EDGAR | RXST 8-K: 2.02 and (SEC Filing) |
| 2024-05-06 | -0.3% | legal | SEC EDGAR | RXST 8-K: 2.02 and (SEC Filing) |
| 2024-04-23 | -0.2% | legal | SEC EDGAR | RXST 8-K: 1.01 (SEC Filing) |
| 2022-05-05 | -0.2% | legal | SEC EDGAR | RXST 8-K: 2.02 and (SEC Filing) |
| 2021-07-30 | — | news | Stock Titan | Latest RXST News - RxSight Highlights 300,000 Light Adjustable... - Stock Titan |